<DOC>
	<DOCNO>NCT00915382</DOCNO>
	<brief_summary>The urgent need new effective therapy well safety profile metastatic gastric cancer patient promise result observe far study S-1 plus cisplatin combination advance gastric cancer ( AGC ) strongly warrant comparison 3-weekly schedule 5-weekly schedule S-1 plus cisplatin standard regimen first-line treatment AGC patient . The objective study compare 3-weekly schedule 5-weekly schedule S-1 plus Cisplatin combination term efficacy , quality life safety patient previously untreated advanced recurrent unresectable gastric cancer . Primary endpoint progression-free survival . This open label , randomize , multi-center , non-inferiority/superiority ( 3-weekly regimen 3-weekly regimen ) hybrid study .</brief_summary>
	<brief_title>Trial 3-weekly Versus 5-weekly Schedule S-1 Plus Cisplatin Gastric Cancer</brief_title>
	<detailed_description>The primary endpoint study Progression Free Survival ( PFS ) . It define time date randomization time disease progression assess investigator , death due cause . The primary goal study compare two different schedule S-1 plus cisplatin combination treatment ( 3-weekly regimen vs. 5-weekly regimen ) advance gastric cancer respect PFS base hybrid design test superiority non-inferiority trial ( Reference : Journal Clinical Oncology 25 : 5019-5023 , 2007 , Boris Freidlin , et el ) . First , non-inferiority hypothesis test base non-inferiority margin 1.15 . If inferiority reject ( mean non-inferiority proven ) superiority test . If superiority test positive , superiority conclude ; otherwise non-inferiority without superiority conclude . The sample size calculate follow consideration : For non-inferiority test : non-inferiority margin 1.15 , 10 percent reduction hazard ratio , power 80 percent , alpha 0.025 , accrual period 36 month , follow-up period 12 month , expect median PFS 6 month 5 weekly regimen assume . Based consideration , total 560 patient need . With 10 percent follow-up loss , need 622 patient . For superiority test : median PFS 5-weekly regimen expect 6 month 7.5 month 3-weekly regimen . With sample size 560 patient calculate , detect 1.5 month difference median PFS two group , 81 percent power , one-sided 5 percent type I error . Using log rank test assume exponential underlying distribution , accrual period 36 month , minimum 12 month follow-up last enrolment , 516 event need show superiority 3 week cycle .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically document metastatic recurrent gastric adenocarcinoma include adenocarcinoma gastroesophageal junction Age 18 74 year old Performance status ( ECOG scale ) 02 No significant problem oral intake drug administration At least one measurable evaluable disease define RECIST Adequate bone marrow function ( ANC ≥ 1,500/uL , Platelet ≥ 100,000/ uL , Hb ≥ 9.0 g/dl ) Adequate renal function : serum creatinine ≤ UNL ( serum creatinine &gt; UNL , creatinine clearance ≥ 60 mL/min ) Adequate hepatic function ( Total bilirubin &lt; 2 x UNL AST/ALT level &lt; 3 x UNL without liver metastasis , total bilirubin &lt; 3x ULN AST/ALT level &lt; 5 x UNL liver metastasis ) Prior systemic therapy ( instance , cytotoxic chemotherapy active/passive immunotherapy ) allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrolment study ) cisplatin use Patients sign write informed consent study entry Tumor type adenocarcinoma Previously expose fluropymidine within 6 month study Previously expose Platinum therapy regardless period and/or duration Microscopic residual disease noncurative gastrectomy R1 resection ( resection margin positive ) Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) Prior radiotherapy administer target lesion select study , radiotherapy nontarget lesion complete within 4 week randomization Presence CNS metastasis Major surgery within 4 week initiation study treatment lack complete recovery effect major surgery ( patient receive curative operation RFA metastatic disease ) Serious illness medical condition : Congestive heart failure ( NYHA class III IV ) Unstable angina myocardial infarction within past 12 month Significant arrhythmias require medication conduction abnormality 2nd degree AV block Uncontrolled hypertension Hepatic cirrhosis ( ≥ Child class B ) Interstitial pneumonia Pulmonary adenomatosis Psychiatric disorder may interfere protocol compliance Unstable diabetes mellitus Uncontrolled ascites pleural effusion Active infection Receiving concomitant treatment interact S1 cisplatin : Flucytosine ( fluorinated pyrimidine antifungal agent ) Antivirals sorivudine , ramivudine , brivudine chemically related agent , warfarin , phenprocoumon , phenytoin , allopurinol Pregnant lactate woman Women child bear potential use contraceptive method Sexually active fertile men use effective birth control medication study drug 6 month completion study drug partner woman childbearing potential Any patient judge investigator unfit participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>